Study of Peresolimab for Adults with Moderate to Severe Rheumatoid Arthritis

2 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment for Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The treatment being tested is called Peresolimab (also known by its code name LY3462817), which is a type of medication known as a humanised IgG1 monoclonal antibody against PD-1. This medication is designed to help the immune system work better in managing the symptoms of rheumatoid arthritis. In this study, some participants will receive Peresolimab, while others will receive a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate how effective Peresolimab is compared to a placebo in improving the symptoms of rheumatoid arthritis. Participants in the study will receive the treatment through a solution for infusion, which means the medication is given directly into the bloodstream. The study will last for a period of time, during which participants will be monitored to see how their symptoms change. The goal is to see if Peresolimab can help achieve a 20% improvement in symptoms, as defined by the American College of Rheumatology (ACR)20 criteria.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how well the treatment works. The study is designed to provide valuable insights into the potential benefits of Peresolimab for people living with rheumatoid arthritis, with the hope of offering a new option for managing this challenging condition.

1 initial visit

Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on your diagnosis of rheumatoid arthritis for at least 3 months.

You will receive detailed information about the study, including the procedures, potential risks, and benefits. You will have the opportunity to ask any questions you may have.

2 baseline assessment

A baseline assessment will be conducted to evaluate your current health status and the severity of your rheumatoid arthritis. This may include physical examinations, blood tests, and questionnaires.

These assessments are important to establish a starting point for measuring the effects of the treatment.

3 treatment administration

You will receive the study medication, which is a humanised igg1 monoclonal antibody against pd-1, administered as a subcutaneous injection. This means the medication is injected under the skin.

The dosage and frequency of the injections will be determined by the study protocol, and you will be informed about the schedule during your visits.

4 regular follow-up visits

You will attend regular follow-up visits to monitor your response to the treatment and any side effects. These visits will include physical examinations, blood tests, and questionnaires similar to the baseline assessment.

The frequency of these visits will be explained to you, and it is important to attend all scheduled appointments to ensure your safety and the accuracy of the study results.

5 final assessment

At the end of the study period, a final assessment will be conducted. This will involve similar procedures to the baseline assessment to evaluate any changes in your condition.

The results of this assessment will help determine the effectiveness of the treatment in achieving a 20% improvement in the American College of Rheumatology core set values, known as ACR20.

Who Can Join the Study?

Must have a diagnosis of adult onset rheumatoid arthritis for at least 3 months. Rheumatoid arthritis is a condition that causes pain and swelling in the joints.
Open to both male and female participants.
Participants must be within the specified age range for the study. This typically means adults, but the exact ages are not specified here.
Includes individuals from vulnerable populations. This means people who might need extra protection or care when participating in a study.

Who Cannot Join the Study?

Patients with any other autoimmune diseases besides rheumatoid arthritis cannot participate. Autoimmune diseases are conditions where the body’s immune system mistakenly attacks its own tissues.
Patients who have had a recent infection or are currently experiencing an infection are not eligible.
Patients who have received any live vaccines within the last 4 weeks cannot join. Live vaccines contain a small amount of the living virus or bacteria.
Patients with a history of cancer in the last 5 years, except for certain skin cancers, are excluded. Cancer is a disease where cells in the body grow uncontrollably.
Patients who are currently pregnant or breastfeeding are not allowed to participate.
Patients with a history of substance abuse or alcohol abuse in the past year are excluded. Substance abuse refers to the harmful use of substances like drugs or alcohol.
Patients who have participated in another clinical trial within the last 30 days cannot join this study.
Patients with severe heart disease or other serious health conditions that could interfere with the study are not eligible. Heart disease refers to various types of heart conditions.
Patients who are unable to comply with the study procedures or follow the study schedule are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
CENTRUM MEDYCZNE REUMA PARK	Warsaw	Poland
Azienda Ospedaliero Universitaria Careggi	Florence	Italy

Other Sites

Site Name	City	Country
Hippokration Hospital	Athens	Greece
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy	Bydgoszcz	Poland
University General Hospital Of Alexandroupoli	Alexandroupoli	Greece
Revita Kft.	Budapest	Hungary
Universidade De Santiago De Compostela	Santiago De Compostela	Spain
Centro Ricerche Cliniche Di Verona S.r.l.	Verona	Italy
University General Hospital Of Heraklion	Heraklion	Greece
Hospital Universitario Basurto	Bilbao	Spain
Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.	Nowa Sol	Poland
Ai Centrum Medyczne Sp. z o.o.	Poznan	Poland
Qualiclinic Kft.	Budapest	Hungary
Ambulatorium Sp. z o.o.	Elblag	Poland
Nova Reuma Domyslawska I Rusilowicz Lekarza Reumatologa I Fizjoterapeuty sp.p.	Bialystok	Poland
Rheuma Medicus Sp. z o.o.	Warsaw	Poland
NIEPUBLICZNY ZAKŁAD OPIEKI ZDROWOTNEJ BIF-MED S.C. A. Wawiernia,M. Roykiewicz,R. Roykiewicz	Bytom	Poland
Twoja Przychodnia Poznańskie Centrum Medyczne Sp. z o.o.	Szczecin	Poland
Vital Medical Center	Veszprem	Hungary
Muhjqyygg Isifltcqkg Ctbobljr Swyrfbog Syw z odrc	Warsaw	Poland
Lzkxk Gokbpja Hsykcyft Ov Amoarb	Athens	Greece
Hxcfkait Uxpjnduthypaf Mnsrhij Db Vorkalmcmj	Santander	Spain
Hcnbijpa Uhjgfgkwmagzf dq A Chospq	A Coruna Galicia	Spain
Uzxhvewiuv Gcckbcc Htesvamy Aagmlev	Athens	Greece

Trial status

Country	Status	Recruitment Start
Greece	Not recruiting	13.03.2023
Hungary	Not recruiting	13.03.2023
Italy	Not yet recruiting	13.03.2023
Poland	Not recruiting	13.03.2023
Spain	Not recruiting	13.03.2023

Trial locations

Investigated drugs:

Peresolimab is a medication being studied for its potential to help people with rheumatoid arthritis, a condition that causes pain and swelling in the joints. This medication is designed to reduce the activity of the immune system, which is often overactive in people with rheumatoid arthritis. By doing so, it aims to decrease the inflammation and pain associated with the disease, helping patients feel better and improve their ability to move and perform daily activities. The study is focused on understanding how well this medication works compared to not taking it at all.

Investigated diseases:

Rheumatoid arthritis

Rheumatoid Arthritis – Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints. It typically begins with inflammation of the synovial membrane, leading to swelling and pain. Over time, the inflammation can cause damage to the cartilage and bone within the joint. This damage can result in joint deformity and loss of function. The disease often progresses symmetrically, affecting the same joints on both sides of the body. It can also cause systemic symptoms, such as fatigue and fever.

Trial ID:

2022-501425-20-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Peresolimab for Adults with Moderate to Severe Rheumatoid Arthritis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?